# Long-Term Effects of Infliximab in the Treatment of Moderate to Severe Psoriasis [Extension of Study P04271, NCT00251641] (P04563)

> **NCT00358670** · PHASE3 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 441 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **BIOLOGICAL:** infliximab
- **BIOLOGICAL:** infliximab

## Key facts

- **NCT ID:** NCT00358670
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-05
- **Primary completion:** 2009-01
- **Final completion:** 2009-01
- **Target enrollment:** 441 (ACTUAL)
- **Why stopped:** Infusion reactions during re-induction cycles after a period of no treatment. Please see "Purpose" section.
- **Last updated:** 2017-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00358670

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00358670, "Long-Term Effects of Infliximab in the Treatment of Moderate to Severe Psoriasis [Extension of Study P04271, NCT00251641] (P04563)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00358670. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*